Abstract
Bangladesh has been combating the COVID-19 pandemic with limited financial resources and poor health infrastructure since March, 2020. Although the government has imposed several restricted measures to curb the progression of the outbreak, these arrays of measures are not sustainable in the long run. In this study, we assess the impact of lift of flexible lockdown on the COVID-19 dynamics in Bangladesh. Our analysis demonstrates that the country might experience second infection peak in 6-7 months after the withdrawal of current lockdown. Moreover, a prolonged restrictions until January, 2021 will shift the infection peak towards August, 2021 and will reduce approximately 20 % COVID-19 cases in Bangladesh.
What we know
Bangladesh has been going through COVID-19 crisis and in response, the Government has implemented restricted array of measures to curb the COVID-19 outbreak in Bangladesh.
What this article adds
The impact of ‘no lockdown’ policies on COVID-19 pandemic in Bangladesh.
Appearance of second infection peak in 6-7 months after the withdrawal of current lockdown.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
The authors declare that no funding was received in order to pursue this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are available with the manuscript
